Australia medicine shortages expose risks for critical drug supply
Australia is facing repeated shortages of critical medicines, with several life-saving drugs remaining hard to source well beyond October 2026. An ABC analysis of Therapeutic Goods Administration data shows more than half of the 40 medicines recently in critical shortage have been affected before, pointing to persistent weaknesses in the country’s pharmaceutical supply chain.
Highlights
- Bicillin L-A has faced its longest recorded critical shortage since April 2025 due to manufacturing issues, with supply not expected until March next year and no adequate substitute available.
- Over half of the 40 medicines in recent critical shortage, including Bicillin and Creon, have experienced repeat shortages, highlighting persistent vulnerability and supply chain risk for essential drugs in Australia.
- Australia imports 90 per cent of its medicines and accounts for only 2 per cent of the global market, with PBS pricing pressures and distance from suppliers further weakening domestic supply chain resilience.
Shortage patterns deepen pressure on essential treatments
As reported by ABC News, an analysis of shortages listed on the Therapeutic Goods Administration website since 2015 shows repeated disruptions across a range of essential medicines, with some current shortages expected to continue into next year.Bicillin L-A, a long-acting penicillin used for patients with syphilis or rheumatic heart disease, entered shortage in April 2025 and is not expected to return to normal supply until March next year. The shortage is classified as critical, meaning it carries a risk of life-threatening or serious impacts and has no adequate substitute in the Australian market. The current disruption is the longest recorded for the drug, with the supplier citing manufacturing issues.
Creon, which helps patients digest food including people with cystic fibrosis, is also in prolonged shortage. Two doses have been hard to source for more than a year because of an unexpected rise in demand, and one dose, Creon 25,000, has already been through multiple shortages in recent years.
Among the 40 medicines recently in critical shortage, more than half have at least one earlier recorded shortage and 13 have been in critical shortage multiple times. Bicillin and Creon are among the most frequently affected, with six shortages each, while other medicines on the list include a Q fever vaccine, a nuclear medicine used for cardiac assessment and an injection for high blood pressure in late pregnancy.
Doctors and researchers warn of supply chain vulnerability
Royal Australasian College of Physicians spokesperson John Saunders says repeated medicine shortages are causing great frustration for doctors, even when alternatives exist. He says substitutes are sometimes less effective or unavailable, making unplanned treatment changes difficult for patients.University of Adelaide pharmacy lecturer Jack Janetzki says repeated critical shortages suggest medicines and their supply chains remain vulnerable to disruption over time. He adds that while authorities are managing shortages through stockpiles and approved unregistered medicines, the broader cost to patients, including time, money and possible health impacts, is not fully understood.
Peter Coomber, a pharmaceutical supply chain researcher at the University of Queensland, says Australia’s medicine supply chain is lacking resilience and remains exposed to disruption. Australia imports 90 per cent of its medicines but accounts for only about 2 per cent of the global pharmaceutical market, which he says makes the country less attractive on market size alone, while PBS pricing pressures and distance from major suppliers add further strain.
The TGA says repeated or long-running shortages are impactful and concerning, but each shortage is unique and dynamic. It says it works with companies and state and territory health departments to resolve disruptions, while government initiatives are aimed at supporting local manufacturing and reducing supply risks, although it cannot compel private pharmaceutical companies to supply medicines in Australia.
Industry groups say shortages can also stem from unforeseen supply chain disruptions, underinvestment in the PBS and the cost of maintaining resilience for low-cost generic medicines. Coomber says Australia should strengthen coordination through a national List of Essential Medicines and build manufacturing capability with regional allies, warning that geopolitical instability and natural disasters could make shortages more frequent.